4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors

US10730880B2 · kind B2 · utility

Assignees

• Array BioPharma, Inc. · US
• CELGENE CORPORATION · US

Inventors

• Shelley Allen · Boulder, US
• Mark Laurence Boys · Lyons, US
• Mark Joseph Chicarelli · Boulder, US
• Jay Bradford Fell · Boulder, US
• John P. Fischer · Boulder, US
• John Gaudino · Longmont, US
• Erik James Hicken · Boulder, US
• Ronald Jay Hinklin · Boulder, US
• Christopher F. Kraser · Boulder, US
• Ellen Laird · Longmont, US
• John E. Robinson · Commerce City, US
• Tony P. Tang · Boulder, US
• Laurence E. Burgess · Boulder, US
• Robert Andrew Rieger · Boulder, US
• Jed Pheneger · Boulder, US
• Yoshitaka Satoh · San Diego, US
• Katerina Leftheris · Skillman, US
• Raj K. Raheja · Poway, US
• Brydon L. Bennett · San Diego, US

Key dates

• Filing date: Dec 6, 2018
• Grant date: Aug 4, 2020
• Expiry date: Dec 6, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.